[Corrections] Correction to Lancet Oncol 2016; 17: 1426–34

Stintzing S, Modest DP, Rossius L,et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. Lancet Oncol 2016; 17: 1426–34—In the appendix, page 9, supplementary table 3, the values for ORR 'central independent review board' should have read '113/157 (72·0%)' and for the Difference '3/157 (1·9%)' in the FOLFIRI plus cetuximab group.

http://ift.tt/2f6LrbH